menu
    • menu
    [{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Vitamin E","moa":"SEC14-like protein 4; SEC14-like protein 3; SEC14-like protein 2; Nuclear receptor subfamily 1 group I member 2; Protein kinase C beta type; Polyunsaturated fatty acid 5-lipoxygenase; Protein kinase C alpha type; Diacylglycerol kinase alpha; Serine\/threonine-protein phosphatase 2A catalytic subunit beta isoform; Serine\/threonine-protein phosphatase 2A catalytic subunit alpha isoform","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zhejiang Medicine Co Ltd \/ R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang Medicine Co Ltd \/ R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ascletis Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Ascletis Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASC41,Aramchol meglumine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Galmed Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Galmed and Ascletis Subsidiary Gannex Expand Development Programs For NASH Through Research Collaboration of A...

                            Details : ASC41 is an oral thyroid hormone receptor beta agonist and Aramchol is a novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, linked by a stable amide group. The team will work together combining both the therapies for the treat...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 10, 2020

                            Lead Product(s) : ASC41,Aramchol meglumine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Galmed Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zhejiang Medicine Co Ltd

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Zhejiang Medicine Co Ltd

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin E

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis

                            Details : Vitamin E is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            November 11, 2016

                            Lead Product(s) : Vitamin E

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth